Budget Amount *help |
¥142,480,000 (Direct Cost: ¥109,600,000、Indirect Cost: ¥32,880,000)
Fiscal Year 2015: ¥25,870,000 (Direct Cost: ¥19,900,000、Indirect Cost: ¥5,970,000)
Fiscal Year 2014: ¥25,870,000 (Direct Cost: ¥19,900,000、Indirect Cost: ¥5,970,000)
Fiscal Year 2013: ¥27,430,000 (Direct Cost: ¥21,100,000、Indirect Cost: ¥6,330,000)
Fiscal Year 2012: ¥27,040,000 (Direct Cost: ¥20,800,000、Indirect Cost: ¥6,240,000)
Fiscal Year 2011: ¥36,270,000 (Direct Cost: ¥27,900,000、Indirect Cost: ¥8,370,000)
|
Outline of Final Research Achievements |
We aimed to elucidate the mechanism for glial cells in recognition and response to neurodegeneration in amyotrophic lateral sclerosis (ALS). We identified an innate immune adaptor, TRIF and astrocyte derived cytokine, TGF-β1 as a detrimental factor of ALS related to glial cells. In addition, we found that osteopontin (OPN), known as a immune and inflammatory mediator, expressed specifically in motor neurons resistant to degeneration in ALS, and modified neuroinflammation through secretion to neighboring glial cells.
|